Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Lecia V. Sequist(Harvard University), Martin Schüler(German Cancer Research Center), Wu‐Chou Su(National Cheng Kung University Hospital), Jaafar Bennouna(Hôpital Foch), Nobuyuki Yamamoto(Wakayama Medical University), Kenneth J. O’Byrne(Translational Research Institute), Vera Hirsh(Taipei Veterans General Hospital), Dan Massey(Taipei Veterans General Hospital), Sarayut Lucien Geater(Prince of Songkla University), James Chih‐Hsin Yang(National Taiwan University Hospital), Tony Mok(Chinese University of Hong Kong), Victoria Zazulina(Taipei Veterans General Hospital), Michael Boyer(Chris O’Brien Lifehouse), Chun‐Ming Tsai(Memorial Sloan Kettering Cancer Center), Terufumi Kato(Taipei Veterans General Hospital), Riyaz Shah(Maidstone and Tunbridge Wells NHS Trust), В. А. Горбунова(Taipei Veterans General Hospital), Ki Hyeong Lee(Chungbuk National University Hospital), Mehdi Shahidi(Taipei Veterans General Hospital), С. В. Орлов(St Petersburg University)
Cited by 3,197
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k